MImAbs is a unique integrated platform that generates and validates therapeutic antibodies in Oncology and Inflammation. A multi-disciplinary team, with expertise ranging from antibody generation to pharmacological validation, can manage all preclinical steps from discovery to pre-CMC development. MImAbs clients include start-ups and biotechs, public technology transfer offices, and biopharma companies.
117 Avenue de Luminy, 13009 Marseille
Targeting innovation : breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, supportive care, liver cancer, brain cancer, head & neck cancer, gastrointestinal cancer, gynecological cancer, bone cancer, genitourinary cancer, skin cancer, hematologic cancer, lymphoma, myeloma, leukemia, predictive toxicology.